Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
Earnings Data
Report Date
May 31, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-2.88Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 21, 2025
|% Change Since: -21.36%
|Next Earnings Date:May 31, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with record sales, FDA approval for extended treatment options, successful restructuring of agreements, and improved financial metrics. However, the net loss in Q4 and minimal unit growth for Ameluz are notable concerns.Company Guidance
During the call, Biofrontera Inc. provided guidance highlighting a record sales year in 2024, achieving $37.3 million in sales, reflecting a 9.5% increase from 2023 and an 18.5% growth in Q4 alone. The company placed 100 RotoLite XL lamps since their launch in June 2024, and successfully negotiated a reduction in the transfer price of Ameluz from 50% to 25% for 2024 and 2025. They also achieved FDA approval to use up to three tubes of Ameluz per treatment and reported progress in a phase three study for Ameluz in treating superficial basal cell carcinoma. Financially, the company reported a net loss of $17.8 million for the year, an improvement from the previous year's loss of $20.1 million, and ended the year with $5.9 million in cash and cash equivalents. They raised $14.8 million through financing activities and maintained stable SG&A and R&D expenses. Looking forward to 2025, Biofrontera anticipates leveraging their strategic initiatives and cost management to continue growth and aim for cash flow positivity.Record Sales Year
Sales reached $37.3 million in 2024, with an annual growth of 18.5% for Q4 and almost 10% for the year, marking a record for the company.
FDA Approval and Product Expansion
FDA approved the use of up to three tubes of Ameluz per treatment, complementing the RotoLite XL lamp launch and expanding treatment capabilities.
Phase Three Study Success
Significant results achieved in a phase three study of Ameluz for treating superficial basal cell carcinoma, with plans to submit data to the FDA.
Successful Agreement Restructuring
Restructured agreements with Biofrontera AG, reducing the transfer price from 50% to 25% for Ameluz purchases in 2024 and 2025.
Improved Financial Performance
Adjusted EBITDA improved to negative $15.3 million in 2024 from negative $19.5 million in 2023, driven by increased sales and reduced SG&A expenses.
Cash Position Strengthened
Cash and cash equivalents increased to $5.9 million as of December 31, 2024, up from $1.3 million in 2023, due to strong growth and additional capital raised.
---
BFRI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BFRI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 21, 2025 | $1.03 | $0.86 | -16.50% |
| Nov 13, 2024 | $0.83 | $0.70 | -15.66% |
| Aug 14, 2024 | $1.14 | $1.16 | +1.75% |
| May 15, 2024 | $1.21 | $1.09 | -9.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biofrontera (BFRI) report earnings?
Biofrontera (BFRI) is schdueled to report earning on May 31, 2025, TBA Not Confirmed.
What is Biofrontera (BFRI) earnings time?
Biofrontera (BFRI) earnings time is at May 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BFRI EPS forecast?
BFRI EPS forecast for the fiscal quarter 2025 (Q1) is -0.22.
---